Biotechnology company Adicet Bio Inc (NASDAQ: ACET) announced on Monday that it has opened enrollment for a Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and ANCA-associated vasculitis (AAV).
The trial, which will assess safety and tolerability, has activated clinical sites for LN patients, with enrollment for SLE, SSc and AAV expected in Q4 2024.
ADI-001, an allogeneic gamma delta CAR T cell therapy targeting B-cells via an anti-CD20 CAR, recently received FDA Fast Track Designation for relapsed/refractory class III or IV LN.
The trial's secondary objectives will focus on cellular kinetics, pharmacodynamics and disease activity.
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Redwire partners with Bristol Myers Squibb for space-based drug research
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Merck acquires CN201 from Curon Biopharmaceutical
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases